Hemoglobin A1c Level and Future Cardiovascular Events among Women

Archives of Internal Medicine

Volumn 164, Issue 7, 2004, Pages 757-761

  Blake, Gavin J ^a,b,d   Pradhan, Aruna D ^a,b   Manson, JoAnn E ^b   Williams, G Rhys ^c   Buring, Julie ^b   Ridker, Paul M ^a,b   Glynn, Robert J ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MATHEMATICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; BLOOD; BODY MASS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BODY MASS INDEX; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 1842681503     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.7.757     Document Type: Article

References (17)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
2. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002;105:2231-2239.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
4. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-1255.
5. Moss SE, Klein R, Klein BE, Meuer SM. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med. 1994;154:2473-2479.
6. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
7. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949-950.
8. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999;33:612-619.
9. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
10. Bjomholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999;22:45-49.
11. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. Diabetes Care. 1996; 19:450-456.
12. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
13. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
14. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J. 1991;121: 1283-1288.
15. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
16. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-2698.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.